drugset / Trial / NCT00003779

Biological Therapy in Treating Patients With Bladder Cancer

NCT00003779

Phase 3 Completed 40 enrolled Swiss Cancer Institute
RandomizedFactorialOpen-labelTreatment

Summary

RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known which type of BCG is more effective for bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different types of BCG in treating patients who have bladder cancer.

Timeline

Start
1998-11
Primary completion
2001-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator BCG Tice Vaccine Other
Comparator Mycobax Vaccine Other